IM Cannabis is divesting its subsidiary IMC Holdings Ltd. to Slil.com Holding Ltd., a related party, to reduce corporate liabilities and strengthen working capital. This strategic move aims to refocus the company on its core Israeli medical cannabis business, but the reliance on financial hardship exemptions for a related-party transaction raises governance concerns.
IM Cannabis is undergoing a significant restructuring by selling its IMC Holdings Ltd. subsidiary to a related party, Slil.com Holding Ltd., controlled by its CEO. This move is intended to shed liabilities (up to CA$9.4 million in assumed debt) and improve working capital, allowing the company to concentrate on its more profitable Israeli medical cannabis operations. While the company claims the deal will enhance shareholder equity by CA$3 million, the use of financial hardship exemptions to bypass formal valuation and minority shareholder votes for a related-party transaction is a red flag for governance and investor confidence. The immediate market reaction was negative, with IMCC shares falling, indicating investor skepticism about the terms and implications of the deal, especially given the company's 'severe financial difficulty.' Short-term, this could provide some financial relief, but long-term, the governance concerns and the company's underlying financial health remain critical risks for traders.